CAJ | 학술논문

弥漫大B细胞淋巴瘤(DLBCL)是最常见的成人非霍奇金淋巴瘤.现阶段利妥昔单抗与CHOP方案(环磷酰胺+多柔比星+长春新碱+泼尼松)的联合应用已显著改善了DLBCL的预后,约50％的DLBCL可以治愈.但由于肿瘤的异质性,对于难治、复发的DLBCL仍然缺乏行之有效的治疗方法.随着基因表达谱的运用及对淋巴瘤细胞内活化信号途径的深入研究,发现了很多潜在的治疗靶点.
미만대B세포림파류(DLBCL)시최상견적성인비곽기금림파류.현계단리타석단항여CHOP방안(배린선알+다유비성+장춘신감+발니송)적연합응용이현저개선료DLBCL적예후,약50％적DLBCL가이치유.단유우종류적이질성,대우난치、복발적DLBCL잉연결핍행지유효적치료방법.수착기인표체보적운용급대림파류세포내활화신호도경적심입연구,발현료흔다잠재적치료파점.
The diffuse large B cell lymphoma (DLBCL) is the most common adult non-hodgkin lymphoma.At present,rituximab in combination with CHOP program has significantly improved the prognosis of DLBCL,and about 50％ of the DLBCL can be cured.However,due to the heterogeneity of the tumor,the refractory and relapsed DLBCL is still lack of effective treatment methods.With the application of gene expression profile (GEP) and the thorough research of the activation of lymphoma cells signal way,a lot of potential therapeutic targets have been found.